Second pivotal study bodes well for VBI's hep B vaccine
Investors of VBI Vaccines were unimpressed last year when the company’s hep B vaccine fell short in comparison to GSK’s established Engerix-B in a key …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
